Dr. John Castle is Associate Vice President, Head of Translational Sciences, at Agenus, lnc. Dr. Castle has deep expertise in biomarkers and therapy development using computational immunology, bioinformatics, biotechnology, and genomics. Having built translational bioinformatics and genomics units focused on immunotherapies, Dr. Castle pioneered the computational approach to the identification of immunogenic peptides for anti-tumor immunity. His bioinformatics approach has revolutionized Agenus’ neoantigen vaccine platform, now in clinical testing. Prior to joining Agenus, he served as associate director at Rosetta lnpharmatics/Merck & Co. and subsequently served as the co-director at the Biomarker Development Center of Translational Oncology at the University of Mainz, Germany. Dr. Castle was the director of bioinformatics at BioNTech AG (DE). Dr. Castle studied physics at Rice University (U.S.), in Gdttingen (DE), and in Canberra (Fulbright to AUS) and received a Ph.D. in geophysics from the University of Washington in Seattle.